Dermatology Times, December 2024 (Vol. 45. No. 12)

In this month’s Cosmetic Conundrums column, learn how radiant, luminous skin can be achieved with cosmeceuticals.

With the right strategies and a clear vision, retirement can unfold as a rewarding chapter.

Karan Lal, DO; Lisa Swanson, MD; James Song, MD; Andrew Alexis, MD, MPH; and Lawrence Eichenfield, MD, discussed the complexities of vitiligo care and the potential of innovative topical therapies.

Take a look back at this year's newly FDA-approved dermatology devices and drugs.

Michael Lewitt, MD, FAAD, highlighted the importance of personalized care, the decision-making process in psoriasis treatment, and the role of patient education.

Join Dermatology Times’ quarterly editor in chief Aaron Farberg, MD, as he highlights significant advancements in gene expression profile testing for cutaneous melanoma.

Join Dermatology Times’ quarterly editor in chief Raj Chovatiya, MD, PhD, MSCI, as he reviews key updates in atopic dermatitis.

Join Dermatology Times’ quarterly editor in chief Christopher Bunick, MD, PhD, as he discusses transformative advances in psoriasis care.

Join Dermatology Times’ quarterly editor in chief Shanna Miranti, MPAS, PA-C, in a look back at acne milestones in 2024 such as topical clindamycin, adapalene, and benzoyl peroxide gel (Cabtreo).

2024 saw significant progress in vitiligo treatments, including novel drugs, off-label uses, and updated pediatric guidelines for better outcomes.

Discover 2024 skin cancer breakthroughs, including FDA approvals, innovative therapies, and updated clinical guidelines for melanoma and nonmelanoma care.

Fall Editor in Chief Raj Chovatiya, MD, PhD, MSCI, celebrates the joy of diverse traditions and reflects on the path to equity in dermatology as we move toward a brighter 2025.

A reflection on 2024's dermatology advancements, from FDA approvals to expert insights, setting the stage for another transformative year in 2025.

Case studies demonstrate success with radiofrequency microneedling for hypertrophic scars in Fitzpatrick IV through VI.

Murase discussed safe dermatologic treatments during lactation, especially for chronic conditions needing biologics.

Murase identifies 4 main pregnancy dermatoses—atopic eruption, polymorphic eruption, extrahepatic cholestasis, and pemphigoid gestationis—as "baby bumps."

Christopher Bunick, MD, PhD, presented the latest period 2 data at Fall Clinical 2024.

Clinicians presented a panel-style session at Fall Clinical, touching on the drawbacks of topical steroid use and alternatives in AD patients.